chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Swelling of face, numbness & tingling of left arm, left leg, & foot. Blurred vision,  sudden onset of headache, heart palpitations
Received shingles shot on 7/28.  By 7/29 unbelievable pain on left side of arm where shot administered from neck, shoulder, arm and hand.  Reported to pharmacy on 8/1.  Said I was having an adverse reaction to shingles shot.  Went to emergency room on 8/4.  Took 8 vials of blood, gave me ekg because left side-everything negative.  Gave me steroids and pain meds.,  Pain did not abate, went to my doctor's office on 8/5, for excruciating pain. Pain has been debilitating.  i am currently on neurotin and pain meds, hot and cold compresses, massage and pain patches.  It has almost been two weeks.  I feel like I have the nerve pain after someone has experienced shingles.  It has been debilitating and I wonder when it will end. Iwill probably go back to doctors by next week if I do not see significant improvement in function and pain.  All over a shingles shot!!!!!!!!
child was exposed to sibling who recv vax & child exp secondary transmission;26JUN97 pt exp chickenpox w/vesicular rash over trunk;
She got vaccinated in Feb. She says her disease has improved and is almost gone.; got the Pfizer booster shot last night, 16Aug2021; got the Pfizer booster shot last night, 16Aug2021; This is a spontaneous report from a contactable consumer (patient herself) from a Pfizer-sponsored program COVAX US Support. A 65-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EL9262), via an unspecified route of administration on 04Feb2021 (age at vaccination 65 years) as DOSE 2, SINGLE; dose 3 via an unspecified route of administration on 16Aug2021 (Batch/Lot Number: FC3181) as DOSE 3, SINGLE for covid-19 immunisation. The patient's medical history included mycobacterium avium complex infection and emphysema. Concomitant medication(s) included tiotropium bromide monohydrate (SPIRIVA RESPIMAT) taken for emphysema. On an unknown date, the patient she got vaccinated in February 2021, she says her disease has improved and is almost gone. On 16Aug2021, the patient got the Pfizer booster shot last night. On an unknown date, the patient underwent lab tests and procedures which included bronchoscopy with unknown results, computerised tomogram was normal and MAC had drastically improved, it's hardly there. She is on a thyroid pill and she also takes Spiriva Respimat for her emphysema. She clarifies she had been on these medications for a while (prior to getting the COVID-19 vaccines) and were not new medications. The outcome of the events was unknown. There was no product quality complaint (PQC) present.
Slight aches, moderate headache, grogginess, low grade fever. This only lasted a few hours, thankfully.
7 days after vaxs, devel swollen R testicle, fever of 102 R, rash on trunk, face, arms. At ER, utrasound of testicles, bld & urine analysis normal. Pain, swelling in testicles & rash lasted 1 wk. Given acetaminophin.
I woke up in the middle of the night with R hand numbness, tingling, and significant swelling in the pointer and middle finger.  The numbness lasted several hours.  During this time of wakefulness, I also experienced the feeling of pins and needles in waves over my body--mostly in my torso and upper body.  I experienced a tingling/nerve response in my intestines as well.  The next morning, the swelling in my fingers had gone down but had not resolved.  That day, I also experienced numbness in my feet--mostly in my heels and the feeling of atrial fluttering.  The fluttering lasted no more than a few seconds but happened numerous times that day.  I had lingering but lessing episodes of numbness/tingling/pins and needles throughout my body for several days until they wholly resolved without intervention about 3 days after the onset.
Patient developed multiple blood clots in lower extremity from unknown origin and presented to ER on 5/25/22. Patient got ultrasound and was administered blood thinners in the ER and sent home on them for an additional 30 days.
Injection site pain; This is a spontaneous report from a contactable consumer or other non hcp (reporters father). A 60-years-old male patient received BNT162B2 (Pfizer-Biontech Covid-19 Vaccine, Formulation: solution for injection, Batch/Lot Number unspecified, expiration date unspecified), via an unspecified route of administration on 26Mar2021 as DOSE 1, SINGLE for covid-19 immunization (60 year at the time of vaccination). The patient medical history and concomitant medications were not reported. On 26Mar2021, the patient experienced injection site pain. And the reporter wanted to know if the patient can take Tylenol/ibuprofen. The outcome of the was reported as unknown at the time of report.  No follow-up attempts are possible. No information about lot/batch number cannot been obtained.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. On or about 12-OCT-2012, the patient received the ZOSTAVAX (lot number, dosage and route of administration not provided), for its intended purpose the prevention of shingles. On 16-OCT-2016, the patient suffered from a shingles outbreak; in addition to chronic pain, rash and lesions to various parts of his" (conflicting information states patient is a female) body as a direct result of the ZOSTAVAX. As a direct result of ZOSTAVAX vaccine, the patient suffered mental and emotional distress due to resulting physical limitations and seriousness of her condition. The patient has sustained severe and permanent personal injuries, suffered serious, progressive, and incurable injuries, as well as conscious pain and suffering, mental and emotional distress, loss of enjoyment of life, physical impairment and injury. The patient has incurred medical expenses and other economic harm as a direct result of ZOSTAVAX use. The outcome of the event was unknown. Causality assessment was related. The event of shingles outbreak was considered disabling. Additional information has been requested.
pt recvd vax;had fever of 103.5,2-3 hrs p/ vax;to MD;given apap & plenty of liquids;mom states that had "cat cry",was sluggish; on 11aug94 t remained 102; pt sleeping quite a bit; MD felt was rxn to immun;
received only MenCYW-135 liquid; received only MenCYW-135 liquid; This case was reported by a nurse via sales rep and described the occurrence of inappropriate preparation of medication in a patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis.   On an unknown date, the patient received Menveo. On an unknown date, unknown after receiving Menveo, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.   Additional Information: GSK Receipt Date: 16-MAY-2022 Reporter's Comments: The registered nurse reported that the patient received only vial containing MenCYW-135 liquid and this Menveo vaccine required reconstitution with liquid and powder and this was not done prior to administration. The reporter reported that this was an error that would have been caught if used GlaxoSmithKline bands. The reporter asked were GlaxoSmithKline interested in having bands delivered to the site. Additional Supportive Information: The registered nurse reported that the patient received only vial containing MenCYW-135 liquid of Menveo, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered.
58 yo female with diffuse large B cell lymphoma was admitted to the hospital on 7/17 for fever and cough and found to be COVID+. She is s/p cycle 2 of R-CHOP chemotherapy, last given on 7/8. She is also s/p full Pfizer COVID-19 vaccination: First dose 6/10/21, second dose 7/1/21. Treated initially with 5 day course of remdesivir, dexamethasone and Levaquin, however on day 5 of treatment, patient developed new oxygen requirement up to 4L. Pt left hospital against medical advice on day 6, discharged on dexamethasone and oxygen. Readmitted to the hospital on 7/22 with complaint of shortness of breath and lethargy.
Chronic Urticaria/Hives and a rare rash called Pemphigus Foliaceus.
We got the 1st dose, can't afford to pay for 2nd dose; This case was reported by a consumer via interactive digital media and described the occurrence of product availability issue in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on an unknown date).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced product availability issue. On an unknown date, the outcome of the product availability issue was unknown.       Additional Information: GSK Receipt Date: 27-May-2022 Reporter's Comments: This case was reported by a patient via interactive digital media. The patient got 1st dose of shingrix. The patient lost medical insurance and when she went to pharmacy they said it would cost 165 dollar. The patient could not afford for that. The patient asked what was the repercussion as the patient already received 1st dose. Additional Supportive Information: Till the time of reporting the patient received the patient did not received 2nd dose of shingrix which led to product availability issue. The case was linked with the case US2022AMR085716, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2022AMR085716:Same reporter.
At 4:00am the day after the Johnson & Johnson vaccine, I woke up with a migraine headache, a fever, chills, muscle soreness, and dry throat.  I could hardly raise my head off of the pillow.  I was extremely sick for over 24 hours.  Four days later, I'm still dizzy and light headed, no appetite and foggy.
Nausea; I felt tired; My stomach hurt constantly; Loss appetite; A spontaneous report  was received from a consumer who was an 60-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced nausea, loss of appetite, stomach pain and felt tired.  The patient's medical history was not provided. No concomitant medications were reported.  On 31 Dec 2020, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (Lot number: unknown) intramuscularly for prophylaxis of COVID-19 infection. On the same day, the patient experienced, nausea and felt tired.   On 31DEC2020, the patient experienced, loss of appetite and stomach pain which she assumed was due to taking ibuprofen with out food. The patient reported that she is healthy, she runs and is a vegan and also that she wasn't ill before the vaccination.   The treatment for the events included ibuprofen.  Action taken with mRNA-1273 in response to the events was not provided.  The outcome for the events, nausea, loss of appetite, stomach pain and felt tired was unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.
Received vaccine on 5/31/07 c/o confusion beginning in 6/01/07-and lasted 10 days-another 10 days didn't "feel well"-skin dry -1 month to 6 weeks later a red discoloration on both arms,  also itchy and later turned brown color. In December skin on legs turned red, itchy and then brown. Saw M.D. regarding confusion- had MRI -results negative- all other test negative. Also c/o aching all over-lasted 10 days after injection.
1. upper left arm has significant swelling, turned reddish and was very firm to touch 2. chills, body soreness, sluggish, congestion with heavy yellowish flam and cough 3. still experiencing mild symptoms a full week later and date of this report 4. my primary care doctor prescribe a 5 day dose of Cefuroxime Axetil 250 MG - one every 12 hours
Swollen, red, warm 31/2X4cm area on Rt. upper arm, where DTaP was given.
SORE THROAT; ABDOMINAL PAINS; TERRIBLE HEADACHE; FATIGUE; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose was not reported, administered on 28-SEP-2021 for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported. On SEP-2021, the patient experienced sore throat. On SEP-2021, the patient experienced abdominal pains. On SEP-2021, the patient experienced terrible headache. On SEP-2021, the patient experienced fatigue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the terrible headache, fatigue, sore throat and abdominal pains was not reported. This report was non-serious.
Mild lower spinal pain the night I received the shot, intense spinal pain the next morning 10/10, I couldn't walk without being in severe pain; I couldn't take a few steps without my legs giving out, I needed objects or other people as support to keep myself up. Has been about an 8/10; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 25 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 06Jan2022 12:00 (Lot number: FL3198) at the age of 25 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "ADHD" (unspecified if ongoing); "Covid-19" (unspecified if ongoing). There were no concomitant medications. The following information was reported: SPINAL PAIN (non-serious) with onset 06Jan2022 21:00, outcome "not recovered", described as "Mild lower spinal pain the night I received the shot, intense spinal pain the next morning 10/10, I couldn't walk without being in severe pain"; GAIT DISTURBANCE (non-serious) with onset 06Jan2022 21:00, outcome "not recovered", described as "I couldn't take a few steps without my legs giving out, I needed objects or other people as support to keep myself up. Has been about an 8/10". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of spinal pain, gait disturbance.  Additional information: no other vaccine in four weeks and no other medications in two weeks. Patient had mild lower spinal pain the night he received the shot, intense spinal pain the next morning 10/10, patient couldn't walk without being in severe pain, he couldn't take a few steps without legs giving out, he needed objects or other people as support to keep up. It had been about an 8/10 as of today (10Jan2021). Patient had no prior health issues.   No follow-up attempts are possible. No further information is expected.
I became very tired and had body aches two days after my second dose of the Moderna vaccine. After that, it had been about four days since I had received my second dose. I started to notice rashes appear all over my body. They were very itchy at times.  So then I went to my local urgent care on May 4th, 2021 to see if they knew what was happening. They prescribed me Hydroxyzine for the itching and Prednisone for the swelling of the rashes. As of May 5th 2021, almost all of the rashes are gone thanks to the medication.
more than 10 weeks since her first dose; minor soreness in her left arm which took her down for a few days; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (more than 10 weeks since her first dose) and MYALGIA (minor soreness in her left arm which took her down for a few days) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (more than 10 weeks since her first dose) and MYALGIA (minor soreness in her left arm which took her down for a few days). The patient was treated with IBUPROFEN (MOTRIN [IBUPROFEN]) for Adverse event, at an unspecified dose and frequency. At the time of the report, PRODUCT DOSE OMISSION ISSUE (more than 10 weeks since her first dose) and MYALGIA (minor soreness in her left arm which took her down for a few days) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were provided by the reporter.
Injection site pain, tiredness, headache, muscle pain, chills, joint pain, fever, injection side swelling, feeling unwell, hot flashes.
HEADACHE; This spontaneous report received from a patient concerned a male of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On AUG-2021, treatment medications included: ivermectin. On 18-AUG-2021, the patient experienced headache.  The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of headache was not reported. This report was non-serious.
According to baby's mother, PT cried constantly for 3 hours beginning approx 3 hrs after receiving the immunizations. He would nurse for short periods of time, and fall asleep for short intervals during this 3 hr period of crying - not a high shrill cry. That night at approx 2:30 a.m., fever was 103 deg; he had received 3 doses of infant Tylenol, 1 dropperful prior to fever. Mother noticed that he seemed "stuffy" and eyes were redenned (described by mother as appearance of "pink eye"). She set up the vaporizer and called pediatrician, who advised her to alternate Motrin and Tylenol every 2 hrs for fever management (according to mother). Fever persisted for 2 days; subsided the night of 3/6/03. On 3/7/03 baby exhibited cold Sx's - cough, congestion and sore throat. Mother continued use of vaporizer. Did not take baby to MD's office. Sx's are subsiding now - 3/12/03.
9pm began with extreme chills and I was burning up but didn?t get out of bed for a thermometer because I was nauseous then began vomiting at 11pm until about 2am
Patient came in for his second dose of Pfizer but did not have his vaccination card with him. After writing him a new vaccination card, he handed me his wallet so I can put it in. However, I noticed he already had a completed vaccination card from a different health care company totaling his administered Pfizer doses to 4. Patient was asked to be monitored for 30 minutes; although, no adverse reactions were present. Also, patient was reassured by staff that he did not need any more vaccinations.
Pt became lethargic but with no loss of consciousness normal vital signs including pox and BP's.  Face and ears became red and ears became swollen.  Had emesis.  Benadryl given initially after emesis (about 1 hour later) phenergan given.  Monitored for 1.5 hour.  No wheezing.  Pt was able to walk on own at discharge.
cramps, dizziness, nervousness, fullness has lasted for 2mo;mostly in AM;no treatment;soft bowel movement;
Swollen lymph nodes in armpit and rash around my entire midsection - stomach to back. Red coloration and bumps. Not itchy.
Hives/ round welps; warmth to touch; Chills/Shivers; feeling cold; Soreness; Redness; Redness; Itchiness; This case was reported by a pharmacist via call center representative and described the occurrence of injection site pain in a 62-year-old male patient who received Herpes zoster (Shingrix) (batch number H549S, expiry date 1st October 2021) for prophylaxis.   On 11th June 2019, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On 11th June 2019, less than a day after receiving Shingrix, the patient experienced injection site pain, injection site erythema, injection site rash and injection site itching. On 12th June 2019, the patient experienced chills and feeling cold. On 13th June 2019, the patient experienced hives and skin warm. The patient was treated with benadryl (nos) (Benadryl) and hydrocortisone. On 13th June 2019, the outcome of the chills was recovered/resolved. On an unknown date, the outcome of the injection site pain, injection site erythema, injection site rash, injection site itching and hives were not recovered/not resolved and the outcome of the feeling cold was recovered/resolved and the outcome of the skin warm was unknown.   It was unknown if the reporter considered the injection site pain, injection site erythema, injection site rash, injection site itching, chills, feeling cold, hives and skin warm to be related to Shingrix.  Additional details were provided as follows: The pharmacist reported that the patient received 1st dose Shingrix in right arm experienced soreness, itchiness and redness (rash) at the injection site.  The pharmacist reported that chills occurred the next day and lasted for that day. Chills described as shivers and getting cold. Itchiness reported as occurring on and off.  It was reported that 2 days after vaccination patient developed hives that went down his arm. The pharmacist described hives as a good sized, round welps that is raised and extends to his wrist and they are warm to touch.  The pharmacist debates if patient should receive 2nd dose and wants to discuss with PCP. The pharmacist advised the patient to use Benadryl and topical like hydrocortisone.
Patient received 0.25mL of Moderna Covid-19 Vaccine, Bivalent; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of UNDERDOSE (Patient received 0.25mL of Moderna Covid-19 Vaccine, Bivalent) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On an unknown date, the patient experienced UNDERDOSE (Patient received 0.25mL of Moderna Covid-19 Vaccine, Bivalent) and NO ADVERSE EVENT (No adverse event). At the time of the report, UNDERDOSE (Patient received 0.25mL of Moderna Covid-19 Vaccine, Bivalent) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for UNDERDOSE (Patient received 0.25mL of Moderna Covid-19 Vaccine, Bivalent).    Concomitant medication was not provided. 196 patients received 0.25ml of Moderna Covid-19 Vaccine, Bivalent. It was unknown if the patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine. Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 27-Dec-2022: Live follow up information received age group was added.
Cellulitis at injection site, doctor attributes event to vaccinations, symptoms appeared same day as vaccination and worsened over the next 2 days.